What question did this study set out to answer?

The aim is to improve risk stratification for progression to cancer in Barrett's esophagus by evaluating aberrant p53 expression.

July 23, 2026Endoscopy

Improving risk stratification in Barrett’s esophagus – time to teach an old dog new tricks

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates aberrant p53 expression for predicting progression in Barrett's esophagus, suggesting new diagnostic approaches.

The aim is to improve risk stratification for progression to cancer in Barrett's esophagus by evaluating aberrant p53 expression.
A multicenter prospective cohort study including 960 Barrett's esophagus patients.
Biopsies were analyzed for p53 expression using immunohistochemistry and histological diagnosis of low-grade dysplasia.
Median follow-up duration of 6.3 years.
Aberrant p53 expression was associated with a 20.00 hazard ratio for progression to high grade dysplasia or esophageal adenocarcinoma.
30% of patients with aberrant p53 progressed, whereas 26% of those with >2 low-grade dysplasia diagnoses did.
Noninvasive sampling methods may reduce unnecessary procedures in patients identified as low risk.

Frei et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates aberrant p53 expression for predicting progression in Barrett's esophagus, suggesting new diagnostic approaches.